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Abstract. Overstimulation of pro‑proliferative pathways and
high level expression of pro‑proliferative transcription factors
(TFs) can lead to apoptosis. This is likely due to TF binding
sites for pro‑proliferative TFs common to pro‑proliferative
and pro‑apoptosis‑effector genes. Certain clinical datasets
have indicated that molecular markers associated with higher
proliferation rates lead to improved outcomes for patients with
cancer. These observations have been extensively assessed on
a general basis, however there has been little work dissecting
feed‑forward apoptosis signaling pathways that may represent
specific distinctions between a pro‑proliferative mechanism
and a pro‑apoptotic mechanism in samples from patients
with cancer. Using The Cancer Genome Atlas datasets and
bioinformatic approaches, the present study reports that higher
FOS expression levels, along with higher FOS target apoptosis‑effector gene expression, is associated with an increased
survival, while higher POU2F1 expression is associated with a
reduced survival (average difference of 25.9 months survival).
In summary, in the datasets examined FOS represents an
apoptosis‑driver and high POU2F1 represents a driver mechanism for cancer development.
Introduction
There are several, distinct pathways that can drive cells into
apoptosis. For example, cross‑linking of major histocompatibility class II molecules apparently represents an S‑phase
independent mechanism of apoptosis (1). Another, basic
pathway involves the over‑accumulation of what would
normally be pro‑proliferative transcription factors (TFs), for
example, E2F1 (2). This over‑accumulation presumably occurs
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in situations where S‑phase is impeded due to a defect in the
cell or due to lack of metabolites or proteins needed for a
complete progression through S‑phase. The over‑accumulation
then leads to occupancy of pro‑apoptosis‑effector genes, by
the pro‑proliferative TFs. This feed forward process of apoptosis is exemplified by over‑activation of the T‑cell receptor
signaling pathway in deletion of self‑reactive T‑cells in the
thymus (3) and by treatment of cells with interferon‑γ (4),
which is pro‑proliferative at lower concentrations and
pro‑apoptotic at higher concentrations. The importance of
a specific pro‑proliferative TF in apoptosis was elegantly
demonstrated many years ago by unexpected tumor development in mice lacking E2F1 (5‑7), a classic pro‑proliferative TF
that stimulates histone gene and dihydrofolate reductase gene
expression (8,9), in preparation for S‑phase. POU2F1 and RB1
have been shown to regulate the interferon‑γ transition from
stimulation of proliferation to stimulation of apoptosis (4,10).
There are several possible and not necessarily mutually exclusive mechanisms to explain the basis of feed
forward apoptosis (FFA). One possibility is based on the
fact that apoptosis‑effector genes are generally smaller than
proliferation‑effector genes (11,12), leading to the proposal
that the occupancy of the apoptosis‑effector genes is simply
due to stochastic processes that favor initial occupancy of
proliferation‑effector genes, and then upon reaching a high
enough intra‑cellular concentration, lead to occupancy of
the apoptosis‑effector genes (12,13). A second possibility,
established via an E2F1 model system (14,15), indicates that
E2F1 binding partners will change in the transition from E2F1
occupancy of proliferation‑effector genes to E2F1 occupancy
of apoptosis‑effector genes.
In the cancer patient setting, evidence of feed forward
apoptosis has been detected in several ways. First, MYC
amplification in neuroblastoma represents a better outcome,
with conventional therapy, unless CASP8 is absent (16). And,
using The Cancer Genome Atlas (TCGA) data, we have
recently reported that an increased number of oncoprotein or
tumor suppressor protein mutations in stomach adenocarcinoma represents a better outcome (17). It is clear that cancer
progression represents a balance of proliferation‑effector and
apoptosis‑effector gene expression, such that proliferation
overcomes apoptosis in case of terminal cancer (18,19). This has
led to the question of whether individual pro‑proliferative TFs
can be classified as supporting apoptosis, presumably despite
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an overwhelming impact of other, specific TFs supporting
proliferation. The results presented below represent one of the
first such identifications of a specific feed‑forward apoptosis
pathway, that is balanced by a specific but distinct pro‑proliferative TF, in a cancer patient setting.
Materials and methods
Basic approaches. RNA microarray values from the metabric
breast cancer dataset representing pro‑proliferative TFs (FOS,
E2F1, JUN, POU2F1, MYC, YY1, STAT3, NFATC1) (20) were
obtained from www.cbioportal.org. The microarray values
and their associated barcodes were organized in descending
order for each TF. The barcodes representing the top 20%
and bottom 20% values were obtained and used as selected
samples for the Kaplan‑Meier (KM) survival curve analysis
tool of cbioportal.org; or for the IBM Statistical Package for
the Social Sciences (SPSS; IBM Corp., Armonk, NY, USA)
software, exactly as described (21) to verify results using
cbioportal.org web tool. The apoptosis‑effector genes used
in this study were obtained from a previous study (12). As
previously shown (12), all apparent human apoptosis‑effector
genes were first obtained on the bases of keyword searches
of the human genome browser database. Then, a set of 34
apoptosis‑effector genes was established by inspection. From
this set of 34 apoptosis‑effector genes, we identified the apoptosis‑effector genes with AP1 (FOS) and POU2F1‑binding
sites within 5,000 base pairs on either side of the gene,
inclusive, using the hg19 genome browser database, with a
z‑score cutoff of 2.33. The microarray values for each of the
apoptosis‑effector genes, with either AP1 (FOS) or POU2F1
binding sites, were obtained from cbioportal.org.
Distinct breast cancer dataset. The RNASeq values of GZMA
were obtained for the TCGA‑BRCA 1105 dataset, from www.
cbioportal.org. The microarray data were then sorted into
descending order to identify top 20% and bottom 20% GZMA
RNASeq values. The averages for top 20% and bottom 20%
were calculated, and associated barcodes were analyzed via
KM approaches as detailed above.
GZMA methylation. The beta‑score, methylation values of the
TCGA‑BRCA GZMA dataset were obtained from cbioportal.
org and processed as previously described (22). The barcodes
were sorted and organized into their respective top 20% and
bottom 20% levels for statistical analyses.
GZMA RNASeq read counts. The RNASeq read counts were
generated by downloading raw RNAseq files from the genome
data commons, via approved NIH dbGaP project no. 6300, and
summing up the reads representing the GZMA section of the
genome.
Statistical analysis. The statistical data in this report are
presented as correlation plots, KM analyses and differences
in the means. For correlation plots, a correlation coefficient
and P‑value were obtained; for the KM analyses, a log‑rank
P‑value was obtained and used to establish significance; and
for the differences in the means, as presented in the Tables,
a Student's t‑test was used to establish significance. Excel

(version 16.12; Microsoft Corporation, Redmond, WA, USA)
was used to obtain correlation coefficients and MedCalc
(version 2017; MedCalc Software, Ostend, Belgium) was used
to obtain the P‑values for the linear correlations. The KM
analyses log-rank P‑values were obtained with the SPSS. For
the majority of the analyses, there were 381 tumor samples
representing the upper and lower quintiles in the analyses.
Results
Association of higher FOS expression with better
survival and relatively high expression of FOS responsive
apoptosis‑effector genes. To determine whether there were
expression levels of pro‑proliferative TFs, that correlated
or inversely correlated with overall breast cancer survival,
we first obtained the microarray values for eight candidate,
pro‑proliferative TFs as tabulated and shown in a previous
study. (12). The purpose of this determination was to identify
candidate TFs, whereby one TF with a high expression level
could be indicative of driving FFA, and thereby be associated
with better survival; and a second TF could, with a high expression level, be associated with a worse survival. Presumably the
latter TF would be driving proliferation in the absence of a
functional FFA process for that TF. The microarray data were
organized into groups of barcodes (samples) that represented
the top 20% and bottom 20% of expression levels for each of
the eight pro‑proliferative TFs (12). The barcodes for those two
groups, for each TF, were compared in terms of the survival
rates, with the remaining barcodes in the dataset, respectively,
using a KM curve, available via a cbioportal.org web tool.
Results indicated that high levels of FOS were associated with
a better survival and that high levels of POU2F1 were associated with a worse survival. The other six TFs did not show a
statistically significant association with either survival status
and were not further considered in this study (Table I).
To confirm the above indication, that high levels of FOS
and POU2F1 represented opposite survival rates, the top 20%
expressers and bottom 20% expressers for each of these TFs
were compared in KM analyses, with results consistent with
the conclusions in the previous paragraph, namely that high
FOS is associated with better survival and high POU2F1 associated with poorer survival (Fig. 1).
To determine whether a higher level of FOS expression
correlated with higher apoptosis‑effector gene expression,
we obtained the RNA microarray values for all of the apoptosis‑effector genes characterized as previously described (12)
that contain an AP1 (FOS/JUN) site within 5,000 base pairs,
inclusive, specifically, UQCRC2, BAD, BAX, and CRADD.
We next sorted the FOS expression levels and obtained the
microarray value averages for each of the AP1 site‑containing
apoptosis‑effector genes listed above for the barcodes that
represented the top 20% and bottom 20% of FOS expression.
We then determined whether the top 20% and bottom 20%
microarray value averages represented significant differences,
in the case of each of these apoptosis‑effector genes. Only
UQCRC2 and CRADD represented statistically significant
differences (Table II). The microarray values for UQCRC2
(in relation to FOS) represented an average of 8.212 for
the top 20% FOS expressers and 7.585 for the bottom 20%
FOS expressers. The results of the CRADD analysis, for the
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Table I. P‑values representing the overall survival differences
for the breast cancer barcodes representing the top and bottom
20% of expression levels (microarray values) for the indicated
transcription factors.
P‑value
Transcription	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
factor
Top 20%
Bottom 20%
FOS
E2F1
JUN
POU2F1
MYC
YY1
STAT3
NFATC1

0.011 (better
overall survival)
0.69
0.10
0.0034 (worse
overall survival)
0.82
0.13
0.37
0.64

0.031 (worse
overall survival)
0.39
0.012
0.0027 (better
overall survival)
0.14
0.42
NS
0.25

NS, not significant; FOS, Fos proto‑oncogene AP‑1 transcription factor
subunit; E2F1, E2F transcription factor 1; JUN, Jun proto‑oncogene
AP‑1 transcription factor subunit; POU2F1, POU class 2 homeobox 1;
MYC, Myc proto‑oncogene BHLH transcription factor; YY1, YY1
transcription factor; STAT3, signal transducer and activator of transcription 3; NFATC1, nuclear factor of activated T cells 1.

Figure 1. Kaplan‑Meier curves for barcodes with high and low expression
of FOS and POU2F1. Top 20% expressers for each TF is represented by the
darker black curve; bottom 20% expressers for each TF is represented by the
lighter gray curve. The log‑rank P‑values for the differences in the survival
rates for (A) FOS and for (B) POU2F1 were P=0.003514 and P=0.000134,
respectively. For FOS, the mean survival difference is 15.3 months. For
POU2F1, 25.9 months. TF, transcription factor; FOS, Fos proto‑oncogene
AP‑1 transcription factor subunit; POU2F1, POU class 2 homeobox 1.

Figure 2. Scatter plots of microarray values for FOS and the two
pro‑apoptosis‑effector genes with FOS binding sites, UQCRC2 and CRADD.
(A) The correlation coefficient plot of FOS vs. UQCRC2 are positively correlated (0.32) with a linear correlation of r2= 0.10. (B) Correlation coefficient plot
of FOS vs. CRADD is positively correlated (0.25) with a linear correlation
of r2=0.06. P<0.0001 for each. FOS, Fos proto‑oncogene AP‑1 transcription
factor subunit; UQCRC2, ubiquinol‑cytochrome C reductase core protein 2;
CRADD, CASP2 and RIPK1 domain containing adaptor with death domain.
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Table II. Comparison of microarray value averages for
apoptosis‑effector genes UQCRC2 and CRADD, for the FOS
high and low expressers in the breast cancer dataset.
Effector
gene
UQCRC2
CRADD

Top 20% FOS Bottom 20%
P‑value
expressers
FOS expressers (top vs. bottom)
8.212
7.385

7.585
7.039

<0.0001
<0.0001

UQCRC2, ubiquinol‑cytochrome C reductase core protein 2; CRADD,
CASP2 and RIPK1 domain containing adaptor with death domain;
FOS, Fos proto‑oncogene AP‑1 transcription factor subunit.

categories of top 20% and bottom 20% FOS expressers, represented an average of 7.385 in the top 20% FOS expressers and
an average of 7.039 for the bottom 20% FOS expressers.
To confirm the correlation of expression levels between
FOS and UQCRC2 or CRADD, we determined the Pearson
correlation coefficient for the FOS microarray values and the
apoptosis‑effector gene RNA microarray values. Both the
UQCRC2 (Fig. 2A) and CRADD (Fig. 2B) apoptosis‑effector
genes showed a linear correlation with the (entire) set of FOS
microarray values. Thus, the correlation data were consistent
with the above described indication that the barcodes representing the top 20% FOS expressers and bottom 20% of FOS
expressers also represented statistically significant differences
in the expression of UQCRC2 and CRADD.
High levels of POU2F1 are generally not associated with
high levels of POU2F1 responsive apoptosis‑effector genes.
As noted above (Table I; Fig. 1B), higher levels of POU2F1
microarray values are associated with statistically significant
worse survival. To determine whether apoptosis‑effector genes
with POU2F1 binding sites represented either more or less
expression when POU2F1 levels were high, we obtained the
microarray values for the following POU2F1‑site containing,
apoptosis‑effector genes: UQCRC2, GZMA, CRADD, CHEK1,
CASP5, CASP3, and COX7B2. We then sorted the barcodes
based on top 20% and bottom 20% POU2F1 expressers. We
next obtained the microarray values for the above indicated
apoptosis‑effector genes (with the POU2F1‑binding sites), for
the top 20% and bottom 20% POU2F1 expression categories,
respectfully (Table III). All of the apoptosis‑effector genes indicated statistically significant differences in expression levels
for the upper and lower POU2F1 expression categories with
the exception of COX7B2. In the case of COX7B2, the microarray values for top and bottom POU2F1 expressers showed
no significant differences. In these POU2F1‑site containing
genes, the barcodes at the highest level of POU2F1 expression had lower levels of apoptosis gene expression, and the
barcodes at the lowest level of POU2F1 expression had higher
levels of apoptosis‑effector gene expression. These results are
consistent with POU2F1 as a cancer driver and a TF that is
not activating what would otherwise be POU2F1‑responsive,
pro‑apoptotic genes (Table III). The one exception to this trend
was CASP3 (Table III). In addition, we determined the Pearson
correlation coefficients for the entire set of microarray values
for POU2F1 vs. UQCRC2, GZMA, and CRADD, respectfully
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Table III. Breast cancer expression levels of POU2F1 transcription factor binding site‑containing, apoptosis‑effector genes.
Transcription factor

Top 20% POU2F1 expressers,
mean microarray value

Bottom 20% POU2F1 expressers
mean microarray value

POU2F1‑independent 			
predictors of survival rates			
UQCRC2
7.41
8.38
GZMA
6.84
7.27
Do not associate with
differing survival rates			
CRADD
6.90
7.45
CHEK1
6.50
6.68
CASP5
5.44
5.46
CASP3
8.67
8.57
COX7B2
5.41
5.43

P‑value

0.0001
0.0001
0.0001
0.0001
0.0558
0.0004
NS

Comparison of POU2F1 transcription factor binding site genes (12). The top 20% and bottom 20% calculated averages of the seven apoptosis‑effector genes, respectively, with binding sites for POU2F1 are indicated. Of the seven, two apoptosis‑effector genes show a clear
distinction in worse overall survival for the top 20% expressers (of the indicated apoptosis gene) compared with the bottom 20% expressers.
These two apoptosis‑effector genes are TF‑independent markers of survival rates. NS, not significant; POU2F1, POU class 2 homeobox 1;
UQCRC2, ubiquinol‑cytochrome C reductase core protein 2; GZMA, granzyme A; CRADD, CASP2 and RIPK1 domain containing adaptor
with death domain; CHEK1, checkpoint kinase 1; CASP, caspase; COX7B2, cytochrome C oxidase subunit 7B2.

(Fig. 3). These three apoptosis‑effector genes were chosen for
the Pearson correlation coefficient analysis because they represented the largest separation of expressions values representing
the top and bottom 20% POU2F1 expressers (Table III). (Also,
these three apoptosis‑genes were studied in the next section
as independent markers of survival.) Results from the Pearson
correlation coefficient analyses (Fig. 3) were consistent with
the above indicated distinctions based on the analyses of the
top 20% and bottom 20% of POU2F1 expressers (Table III).
Apoptosis‑effector genes expression levels as independent
indicators of survival rates. To determine whether the
expression levels of the apoptosis‑effector genes could be
independent indicators of survival distinctions, we sorted
the barcodes based on the microarray values for each apoptosis‑effector gene, without regard for the expression of any
of the TFs. Barcodes representing the top 20% of UQCRC2
microarray expression levels displayed a greater overall
survival rate (P=0.0037) when compared to all remaining
samples (Table IV). And, the barcodes representing the
bottom 20% of UQCRC2 microarray values displayed a worse
overall survival when compared to all remaining samples
(P=0.05) (Table IV). Likewise, barcodes representing the
top 20% of GZMA microarray expression levels displayed a
greater overall survival rate when compared to all remaining
barcodes (P=0.012). And, barcodes representing the bottom
20% of GZMA microarray expression levels displayed a worse
overall survival rate when compared to all remaining samples
(P=0.0032) (Table IV). The expression levels of the remaining
apoptosis‑effector genes (Table III) did not indicate any independent associations with distinct survival rates.
To confirm the above indication, that UQCRC2 and GZMA
represented independent correlations with survival rates, KM
survival curves were created representing in each case the top

Figure 3. Scatter plots of POU2F1 microarray values vs. associated apoptosis‑effector genes UQCRC2, GZMA, CRADD. The linear correlation
coefficient plots of (A) POU2F1 vs. UQCRC2, (B) POU2F1 vs. GZMA and
(C) POU2F1 vs. CRADD are negatively correlated, with r2=0.29, 0.028, 0.21,
respectfully. In all three cases, P<0.00001. POU2F1, POU class 2 homeobox 1;
UQCRC2, ubiquinol‑cytochrome C reductase core protein 2; GZMA, granzyme A; CRADD, CASP2 and RIPK1 domain containing adaptor with death
domain.

20% and bottom 20% expressers, using the SPSS software
(Fig. 4). Results indicated that higher levels of both UQCRC2
and GZMA were associated with better survival rates.
GZMA as an independent indicator for survival rate in a distinct
breast cancer dataset. Overall KM survival curve of patients
representing the top 20% of expressers of the apoptosis gene,
GZMA, in a different breast cancer data set (TCGA‑BRCA,
with 1105 samples), displayed a better survival, compared with
all remaining barcodes (P=0.11). There was a worse survival
rate for the bottom 20% GZMA expressers, compared with all
remaining barcodes (P=0.032). An additional, independently
constructed KM survival curve was created to further verify the
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Table IV. Breast cancer expression levels apoptosis‑effector genes used for survival rate correlations independent of the
pro‑proliferative transcription factors.
Transcription factor

Top 20% apoptosis‑gene
expressers, mean microarray value

Bottom 20% apoptosis‑gene
expressers, mean microarray value

P‑value

8.85
8.63

6.96
5.83

<0.0001
<0.0001

UQCRC2
GZMA

UQCRC2, ubiquinol‑cytochrome C reductase core protein 2; GZMA, granzyme A.

Table V. Granzyme A methylation levels for The Cancer
Genome Atlas‑BRCA dataset.
Data set
TCGA‑BRCA

Top 20%
expressers

Bottom 20%
expressers

P‑value

0.609

0.853

<0.0001

TCGA, The Cancer Genome Atlas.

above information that GZMA displayed significant survival
differences in a second distinct breast cancer dataset (Fig. 5).
GZMA methylation. To consider a mechanistic explanation for
GZMA differences in the expression levels among the TCGA
barcodes, we hypothesized that GZMA methylation could lead
to a repressive chromatin structure and thereby block access to
POU2F1 in the cells representing the barcodes with high POU2F1
levels and relatively low levels of GZMA. Thus, we downloaded
the TCGA‑BRCA methylation data for GZMA and organized
the barcodes into the top 20% and bottom 20% of GZMA
expression levels. (The metabric study did not have methylation
data.) We calculated the GZMA methylation (beta‑score) of the
top 20% GZMA expressers to be 0.61; and calculated the GZMA
methylation for the bottom 20% of the GZMA expressers to be
0.85, representing a higher level of GZMA gene methylation and
a statistically significant difference (Table V).
Raw RNAseq data verification. Because the above analysis was
done with processed data, we sought to verify the final conclusion,
that the apoptosis effector gene, GZMA, represented a robust
biomarker for breast cancer survival. Thus, we downloaded the
original RNASeq files from the genome data commons for the
top and bottom 20% GZMA expressers and obtained read counts
representing GZMA, i.e., hg38 reference genome position,
chr5:55, 102, 648‑55, 110, 252. The average number of reads for
the top 20% expressers was 2698; the average number of reads
for the bottom 20% expressers was 107 (P<0.0001).
Discussion
As indicated by the above analyses, available data are consistent
with the idea that feed‑forward pathways can represent specific
distinctions, based on what have been traditionally considered
pro‑proliferative TFs, between pro‑proliferative and pro‑apoptotic pathways. This conclusion was also recently reached for

Figure 4. Kaplan‑Meier curves for (A) UQCRC2 and (B) GZMA survival
differences. Top 20% of the microarray values for each gene is represented by
the darker black curve. Bottom 20%, by the lighter gray curve. The log‑rank
P‑values for UQCRC2 and GZMA were P=0.000285 and P=0.000971,
respectively. The mean difference in survival times for UQCRC2 and GZMA
were 21.1 and 29.9 months, respectively. UQCRC2, ubiquinol‑cytochrome C
reductase core protein 2; GZMA, granzyme A.

Figure 5. Kaplan‑Meier curves for GZMA survival differences for the
TCGA‑BRCA dataset. Top 20% for the TCGA‑BRCA microarray values is
represented by the darker black curve. Bottom 20% is represented by the
lighter gray curve. The log‑rank P‑value was P=0.022. GZMA, granzyme A;
TCGA, The Cancer Genome Atlas.

lower grade glioma and squamous cell lung cancer (23), where
MYC and YY1, respectively, were identified as apoptosis‑drivers.
These distinctions may be useful in determining a more accurate
overall survival rate among cancer patients, as well as possibly
assist in development of therapies. In this study, low POU2F1
barcodes represented a 25.9 month longer survival, on average.
In the case of the above breast cancer dataset, the analyses
indicated that high levels of FOS were associated with better
survival, and that high levels of POU2F1, as noted in the previous
paragraph, were associated with worse survival outcomes. To
understand the link between FOS and better survival, FOS was
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connected to higher expression of apoptosis‑effector genes,
thereby indicating a credible pathway for FFA, with FOS as the
apoptosis‑driver. In particular, the higher level of FOS expression
was correlated with higher expression of the apoptosis‑effector
genes, CRADD and UQCRC2.
To better understand how lower levels of POU2F1 could
be associated with a higher survival rate, we examined the
POU2F1 relationship with its putatively responsive, apoptosis‑effector genes: UQCRC2, GZMA, CRADD, CHEK1,
CASP5. In all of these cases, the highest level of gene expression was associated with the lowest levels of POU2F1. As noted
in Results, in two cases, there was not an inverse correlation
with POU2F1 expression for the POU2F1 putatively responsive, apoptosis‑effector genes. In these latter two cases, there is
no explanation for the lack of an inverse correlation of expression levels, other than the possibility that the expression of the
two apoptosis‑effector genes does not interfere with POU2F1
as a cancer‑driver due to a mechanism that is not related to
transcriptional activation, for example, micro‑RNA mediated,
negative regulation at the level of translation. Investigations of
such a possibilities will be part of future work.
While the above connections between TFs and apoptosis‑effector genes indicates a mechanism whereby higher
levels of what are traditionally consider pro‑proliferative
TFs could lead to better survival, an additional, practical
issue is, biomarkers for improved for survival rates. As
such, we examined apoptosis‑effector gene expression for
TF‑independent associations with distinct survival rates,
with GZMA and UQCRC2 representing the most important
such biomarker candidates, including the confirmation of
higher GZMA expression levels representing better overall
survival rates in a second breast cancer dataset, namely the
TCGA BRCA dataset. GZMA is expressed at a high level in
cytotoxic T‑cells (24), and none of the above data can indisputably pinpoint the source of the gene expression studied, i.e.,
cancer cells or micro‑environment cells. Thus, it is possible
that the higher level of GZMA represents a higher level of
cytotoxic T‑cell infiltrate that is mediating an increased level
of apoptosis and better survival rates. However, there is no
such specific association of the FOS‑responsive UQCRC2
with immune infiltrate cells, and what data is available indicates mammary tissue and whole blood represent about the
same levels of expression (genome.ucsc.edu), very different
from GZMA.
In sum, the above analyses identified potential FFA signatures in breast cancer with possible insights into therapy design
and likely survival rate, biomarker identification.
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